Vaccines are biological preparations that induce protective immunity against infectious diseases by exposing the immune system to antigens derived from pathogens, generating immunological memory without causing disease. Vaccination is one of the most cost-effective public health interventions, preventing millions of deaths annually from diseases including smallpox, polio, measles, and influenza.
What Are Vaccines?
Vaccines work by presenting antigens to the immune system in a way that activates B cells to produce neutralizing antibodies and T cells for cellular immunity. Immunological memory ensures a rapid and robust response upon subsequent exposure to the actual pathogen. The pharmacological principles of vaccines include antigen selection, formulation, adjuvant use, and schedule optimization.
Drug Classes and Mechanisms
Live attenuated vaccines contain weakened forms of the pathogen that replicate in the host but do not cause disease in immunocompetent individuals. They elicit strong and durable immune responses, often requiring only one or two doses. Examples include measles-mumps-rubella (MMR), varicella, yellow fever, oral polio, and intranasal influenza vaccines.
Inactivated vaccines contain killed pathogens that cannot replicate. They are safer in immunocompromised hosts but require multiple doses and boosters to maintain immunity. Examples include injectable polio, rabies, hepatitis A, and whole-cell pertussis vaccines.
Subunit, recombinant, and conjugate vaccines use purified antigenic components rather than whole pathogens. Subunit vaccines include acellular pertussis and hepatitis B (recombinant surface antigen). Conjugate vaccines link polysaccharide antigens to carrier proteins, enabling T cell-dependent immune responses in infants. Examples include Haemophilus influenzae type b, pneumococcal conjugate, and meningococcal conjugate vaccines.
Toxoid vaccines use inactivated bacterial toxins to generate immunity against toxin-mediated disease. Tetanus and diphtheria toxoids are standard components of childhood vaccination.
mRNA vaccines deliver messenger RNA encoding the target antigen, which host cells translate to produce the antigen and trigger immune responses. The COVID-19 mRNA vaccines (BNT162b2, mRNA-1273) demonstrated remarkable efficacy and accelerated development timelines, representing a platform technology adaptable to other pathogens.
Viral vector vaccines use a harmless virus to deliver genetic material encoding the target antigen. The Johnson and Johnson and AstraZeneca COVID-19 vaccines use adenoviral vectors.
Adjuvants are substances added to vaccines to enhance immune responses. Aluminum salts (alum) are the most widely used adjuvant. Novel adjuvants including MF59, AS01, and AS04 further augment immunogenicity.
Therapeutic Uses
Routine childhood immunization schedules protect against sixteen or more vaccine-preventable diseases. Adult vaccination includes annual influenza, tetanus-diphtheria-pertussis boosters, pneumococcal, zoster, and human papillomavirus vaccines. Travel vaccines address region-specific risks. Pandemic vaccines are developed rapidly in response to emerging infectious disease threats.
Adverse Effects
Common adverse effects include injection-site reactions, fever, and myalgia. Serious adverse events are rare and include anaphylaxis (approximately 1 per million doses), intussusception with rotavirus vaccine, and rare cases of vaccine-associated paralytic polio with oral polio vaccine. mRNA COVID-19 vaccines are associated with rare myocarditis, particularly in young males.
Key Clinical Considerations
Contraindications include anaphylaxis to a previous dose or component. Live vaccines are contraindicated in pregnancy and significant immunosuppression. Herd immunity protects vulnerable populations unable to receive vaccines. Vaccine hesitancy, fueled by misinformation, threatens public health gains and requires evidence-based communication strategies.
Conclusion
Vaccines represent one of medicine’s greatest achievements, dramatically reducing infectious disease morbidity and mortality. Ongoing advances in vaccine technology, including mRNA and viral vector platforms, position vaccinology to respond rapidly to emerging pandemic threats and address diseases for which vaccines remain elusive.
